Living with chronic obstructive pulmonary disease (COPD) can feel like a constant struggle – a life that may be disrupted by debilitating flare-ups and fear of hospitalization. 

Impacting more than 14 million adults, COPD is a progressive disease that damages the lungs and airways making it difficult to breathe. And sadly, it’s a leading cause of death in the U.S.

Here’s the frustrating truth: even with daily maintenance inhalers, nearly half of patients still have dangerous symptom flare-ups, also known as exacerbations. These flare-ups aren’t just inconvenient, they can lead to more frequent and severe flare-ups, and a high risk of hospital admission. Just one flare-up increases the likelihood of recurrent flare-ups and related hospital admissions. Why are these flare-ups so persistent?

Evolving science has shown a critical piece of the puzzle: eosinophilic inflammation. This type of inflammation (swelling) in the lungs can be a driver of COPD symptoms, especially for those who experience frequent flare-ups.

What to know: Including a blood eosinophil test in routine screenings, combined with a doctor’s evaluation and diagnostic tools, can help identify if eosinophilic inflammation is making COPD worse. By understanding an underlying cause of flare-ups, a doctor can develop a targeted treatment plan to manage COPD and potentially reduce the frequency of exacerbations.

Alexis Smith, DO, Pulmonary Disease will discuss the challenges facing those living with COPD to help manage COPD and try to break the cycle of flare-ups.

Interview courtesy: GSK

#COPD #chronicobstructivepulmonarydisease #AlexSmith #GSK

The post SCIENCE SHEDS LIGHT ON THE CHALLENGES OF WORSENING SYMPTOMS FOR MANY appeared first on Good News!.

Medication can help manage symptoms, but treatment benefits often diminish or become less consistent over time. Patients report alternating states between “ON time,” when the medication is working well, and “OFF time,” when it no longer provides symptom benefit and movement-related symptoms return.

These on-again, off-again changes are disruptive and unpredictable – but a new treatment may help.

The FDA recently approved a treatment that offers a new approach to treating these motor fluctuations – without the need to resort to invasive surgery. 

On Wednesday, April 23^rd, during Parkinson’s Disease Awareness Month, we are pleased to offer the opportunity to hear from expert Dr. Stuart Isaacson, Director of the Parkinson’s Disease and Movement Disorders Center. He can discuss the current treatment landscape, the importance of managing OFF episodes and the potential impact of this new treatment.

This interview is sponsored by Supernus.

#parkinsonsdisease #parkinsons #onapgo #supernus

The post Parkinson’s Disease Awareness Month (April) A NEW WAY TO HELP MAKE DAYS WITH PARKINSON’S DISEASE MORE PREDICTABLE appeared first on Good News!.

Schizophrenia is not a one-size-fits-all condition, and people often find themselves in a cycle of discontinuing and switching therapies. Studies have shown that approximately 40% of people with schizophrenia do not respond to therapy, and up to 60% experience a partial or inadequate improvement or intolerable side effects during therapy.

The FDA recently approved a new medication for the treatment of schizophrenia in adults, representing the first new class of medicine in more than 30 years. This new treatment option leverages a novel pathway and represents a new mechanistic approach to addressing the symptoms of schizophrenia.

Dr. Gus Alva, a Distinguished Fellow of the American Psychiatry Association will be available to discuss the significance of this new treatment for adults living with schizophrenia and their care partners, and its potential to transform the treatment landscape.

FOR THE FIRST TIME IN 30 YEARS, THE FDA HAS APPROVED THE FIRST DRUG REPRESENTING A NEW CLASS OF MEDICINE FOR THE TREATMENT OF SCHIZOPHRENIA.

ADULTS LIVING WITH SCHIZOPHRENIA HAVE A NEW TREATMENT OPTION TO HELP MANAGE THEIR CONDITION THAT INTRODUCES A FUNDAMENTALLY DIFFERENT APPROACH TO THE TREATMENT OF SCHIZOPHRENIA.

JOINING US NOW WITH MORE INFORMATION IS DR. GUS ALVA,  DISTINGUISHED  LIFETIME FELLOW OF THE AMERICAN PSYCHIATRY ASSOCIATION.

BIO

Dr. Gus Alva is the medical director of ATP clinical research (a premiere private clinical research company specializing in neuropsychiatric investigations). He is an Associate Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine (UCI). He is a forensic psychiatric consultant for the Orange County Superior Court and a diplomate of the American Board of Psychiatry and Neurology.

Dr. Alva received his medical degree from the Autonomous University of Guadalajara (UAG). Residency training was completed at the University of California, Irvine Medical Center in the Department of Psychiatry and Human Behavior, where he served as chief resident during his final year of residency.

Dr. Alva has served as a principal investigator for the past 10 years conducting investigations in a myriad of neuropsychiatric conditions: Alzheimer’s and other dementias, depression, anxiety disorders, bipolar disorder and psychotic conditions. As a clinician and investigator, Dr Alva’s focus is on the genetics, neuroimaging, and latest treatments available for each aforementioned condition, as well as aspects of ethnicity and their correlation within clinical situations. He has published numerous articles, and presents at both national and international meetings and conferences.

He is the immediate past-president of the Orange County Psychiatric Society. Dr. Alva is also a member of many professional organizations, including the American Medical Association, the Orange County Medical Association, the California Psychiatric Association, the American Board of Forensic Medicine, the American College of Forensic Examiners, the California Hispanic American Medical Association and the International Congress of Geriatric Psychopharmacology.

IMORTANT SAFETY INFORMATION: INDICATION

COBENFY (xanomeline and trospium chloride) is a prescription medicine used to treat schizophrenia in adults.

It is not known if COBENFY is safe and effective in children.

IMPORTANT SAFETY INFORMATION Do not take COBENFY if you:

•        have urinary retention problems that cause your bladder to not empty completely or not empty at all

•        have moderate or severe liver problems (impairment)

•        have gastric retention problems that cause your stomach to empty slowly

•        are allergic to COBENFY, xanomeline, or trospium chloride, or any of the ingredients in COBENFY

•        have an eye problem called untreated narrow-angle glaucoma

Before taking COBENFY, tell your healthcare provider about all of your medical conditions, including if you:

•        have an enlarged prostate, problems passing urine, or a blockage in your urinary bladder

•        have liver problems

•        have or have had gallstones or problems with your bile ducts or pancreas

•        have stomach or intestinal problems, including constipation, ulcerative colitis, slow emptying of your stomach, or myasthenia gravis

•        have an eye condition called narrow-angle glaucoma

•        have kidney problems

•        are pregnant or plan to become pregnant. It is not known if COBENFY may harm your unborn baby. Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with

COBENFY. o               There is a pregnancy exposure registry for women who take COBENFY during pregnancy. The purpose of this registry is to collect information about the health of women exposed to COBENFY and their baby. If you become pregnant during treatment with COBENFY, your

healthcare provider will register you by calling 1-866-961-2388 or online at https://womensmentalhealth.org/research/pregnancyregistry/atypicalantipsychotic/

•        are breastfeeding or plan to breastfeed. It is not known if COBENFY passes into your breast milk or if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. Taking COBENFY with certain other medicines may increase your risk of side effects from COBENFY or the other medicine

The post BREAKING NEW GROUND IN SCHIZOPHRENIA TREATMENT appeared first on Good News!.

THIS SERIOUS, RARE, AND MISUNDERSTOOD CANCER HAS A PRIMARY RISK FACTOR THAT IS MORE PREVALENT THAN YOU MIGHT THINK. HUMAN PAPILLOMAVIRUS OR HPV—A COMMON VIRUS TRANSMITTED BY SKIN-TO-SKIN CONTACT—IS THE NUMBER ONE RISK FACTOR FOR ANAL CANCER.^1,2

MARCH IS ANAL CANCER AWARENESS MONTH. JOINING US TO SPEAK ABOUT THE IMPORTANCE OF TALKING OPENLY ABOUT THE RISK FACTORS AND SYMPTOMS OF THIS CANCER THAT CAN BE DIFFICULT TO TALK ABOUT ARE ANAL CANCER SPECIALIST, DR. PAUL ROMESSER [ROME-EH-SIR], AND LILLIAN KREPPEL [LILL-EE-IN KREH-PELL], ANAL CANCER SURVIVOR AND CO-FOUNDER AND EXECUTIVE DIRECTOR OF THE HPV CANCERS ALLIANCE.

BIO- Paul Romesser, MD

Colorectal and Anal Cancer Specialist

Dr. Paul Romesser is a board-certified radiation oncologist specializing in the treatment of colorectal and anal cancer. He is also actively involved in anal cancer clinical trials. Dr. Romesser is passionate about helping patients navigate the complexities of cancer care and create personalized treatment plans tailored to their needs.

BIO-Lillian Kreppel

Co-Founder and Executive Director of HPV Cancers Alliance

Lillian is an anal cancer “thriver,” patient advocate and the Co-Founder and Executive Director of HPV Cancers Alliance, a 501(c)(3) non-profit organization dedicated to raising awareness of human papilloma virus (HPV) and the cancers it can cause. She was diagnosed with HPV-related anal cancer in 2017 and has been a passionate activist and changemaker for the HPV and anal cancer community ever since.

In her own words, “No one should die from HPV – education and self-advocacy can save your life. HPV desperately needs a voice. I AM THAT VOICE!”

The bottom line: Get informed and speak up about risk factors, symptoms, and better care at all stages

Anal cancer can go undetected as it shares many of the same symptoms as common, non-cancer conditions.1 Further, people experiencing symptoms can be embarrassed to discuss them with their doctor and unaware of the key risk factors for anal cancer, which may lead to a delayed diagnosis. Open and honest communication is critical with this cancer, as early diagnosis may help improve outcomes.2

The #1 risk factor for anal cancer is human papillomavirus (HPV), a common virus transmitted by skin-to-skin contact.2,3 Other key facts about HPV include:

Nearly all sexually active people will be infected with HPV at some point in their lives.4
A healthy immune system will rid most HPV infections within two years before they cause precancer cell changes.4
Approximately 90% of anal cancers are associated with HPV infection.5
While anal cancer is rare, its incidence is on the rise.6
Squamous cell carcinoma of the anal canal (SCAC) is the most common type of anal cancer, accounting for about 90% of all anal cancers.7

On Wednesday, March 19, in recognition of Anal Cancer Awareness Month, Lillian Kreppel, Executive Director and Co-Founder of the HPV Cancers Alliance (hpvca.org), and colorectal and anal cancer specialist, Dr. Paul Romesser, is going to discuss their personal and expert perspectives about the condition and the importance of open conversations with healthcare providers at all stages of the journey.

Together, Lillian and Dr. Romesser aim to raise national awareness of anal cancer and its connection to HPV, as well as inspire more open and comfortable communication and better care at all stages. No one is alone in this journey.

#analcancer #cancer

The post **March is Anal Cancer Awareness Month** appeared first on Good News!.

Over 60 million Americans, about one-fifth of the U.S. population, live in areas where access to healthcare, including IV administration, is often limited. This particularly poses challenges for people with chronic diseases like MS.
Roger was diagnosed with MS when he was 36, and experienced symptoms including migraines, vision loss and leg pain.
However, he has been able to manage his MS thanks in part to a newly approved treatment by the U.S. Food and Drug Administration (FDA).
The treatment is the first and only twice-a-year, 10-minute subcutaneous injection for certain types of MS and provides a new and much needed option for people living with the disease, particularly those who need flexibility in the route of administration or treatment time.
Dr. Robert Shin, Director of the Multiple Sclerosis and Clinical Neuroimmunology Division at UVA Health, is available to discuss the importance of this treatment for MS and will explain how it provides additional choice and flexibility for both healthcare providers and people living with the disease. Roger will also be joining Dr. Shin to talk about his experience with MS and how this treatment option has helped him manage his disease.

Interview is courtesy of Genentech

#ms #managingms #multiplesclerosis #msawarenessmonth #msawareness

The post MS Awareness Month in March NEW OPTION FOR MANAGING MULTIPLE SCLEROSIS appeared first on Good News!.

Liver cancer is the sixth most commonly diagnosed cancer worldwide and third-leading cause of cancer-related deaths in the United States.1,2 Hepatocellular carcinoma, or HCC, is the most common type of liver cancer, yet more than half of patients are diagnosed at advanced stages of the disease often when symptoms first begin to appear.3,4 Historically, the prognosis for advanced HCC has been poor, with only 7% of patients surviving up to five years after diagnosis.4

http://imfinzi.com/

But today, there is reason for optimism. Advances in research and medical innovation are signaling a shift in patient expectations, offering hope for more time for patients navigating their unresectable HCC or uHCC diagnosis. Here to explain the progress being made in the treatment landscape is Dr Shroff [shrawf] with the University of Arizona Cancer Center.

BIO:
Rachna T. Shroff, MD, MS, FASCO, is associate director of Clinical Investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She also is a professor with tenure in the Department of Medicine, Chief of the Division of Hematology and Oncology, and Medical Director for the Oncology Service Line. Dr. Shroff also served as Associate Dean for Clinical and Translational Research for the University of Arizona College of Medicine – Tucson; 2021 – 2024. She came to UACC from MD Anderson Cancer Center in Houston, where she was on faculty from 2010-18 after completing her medical oncology fellowship there.
Research Interests
Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary Subcommittee co-chair for the Southwest Oncology Group (SWOG) and as Chair for GI ASCO 2025, a meeting sponsored by the American Society of Clinical Oncology focused on gastrointestinal cancers. Most recently, she was elected to serve on the ASCO Nominating Committee. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation.

Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which investigated a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.

#livercancer #cancer #drshroff #hcc #hepatocellularcarcinoma

The post Did you know October is Liver Cancer Awareness Month? appeared first on Good News!.

OBSTRUCTIVE H-C-M SYMPTOMS ARE ALSO COMMON SYMPTOMS OF OTHER DISEASES, WHICH MAKES THE DISEASE HARD TO DIAGNOSE.

JOINING US NOW IS SYMPTOMTIC OBSTRUCTIVE HCM PATIENT STEPHANIE ALONG WITH BOARD CERTIFIED CARDIOLOGIST, DR. WILLIAM CROWDER, TO RAISE AWARENESS OF THIS CONDITION IN HONOR OF HEART MONTH IN FEBRUARY. 

Spokesperson Bios

Stephanie, Obstructive HCM Patient

Stephanie is a trained occupational therapist located in Natchez, Mississippi. In 2022, Stephanie was diagnosed with symptomatic obstructive hypertrophic cardiomyopathy, and since then has become passionate about raising awareness of the symptoms and impact of the disease. She is now a part-time yoga teacher who enjoys volunteering, pottery, hiking, walking and spending time with her husband and three sons.

William H. Crowder, MD, board-certified cardiologist, Jackson Heart

Born and raised in Grenada, MS, Dr. Crowder attended Millsaps College where he graduated magna cum laude with a degree in biology. He attended medical school at the University of Mississippi, pursuing training in internal medicine and cardiology. Finally, Dr. Crowder underwent a year of additional training in advanced interventional cardiology techniques at the Medical University of South Carolina. There he trained with national leaders in the interventional cardiology community with an emphasis on atrial septal defect/patent foramen ovale repair as well as techniques for treatment of hypertrophic cardiomyopathy.

He is active in multi-center research trials, staying at the forefront of medical technology.

Dr. Crowder is board certified in internal medicine, cardiovascular disease, and interventional cardiology. His memberships include the Mississippi State Medical Association, the American Medical Association, and the American College of Cardiology. He is a fellow of the College of Cardiology. He has been active in the medical community and is a past member of the board of trustees of the state medical association.

He attends St. Richard’s Church with his wife, Kimberly. When he is not working, he enjoys reading and playing music. He is an accomplished pianist and works with his father on various record projects.

IMPORTANT SAFETY LANGUAGE

This section is for informational purposes only, and should be removed prior to use CAMZYOS CISI 06-15-2023

Indication: Obstructive hypertrophic cardiomyopathy (oHCM)

Last modified on 15/06/2023 08:38:52 PM EST Generated on 05/02/2024 12:20:25 PM EST

INDICATION

CAMZYOS® (mavacamten) is a prescription medicine used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). CAMZYOS may improve your symptoms and your ability to be active. It is not known if CAMZYOS is safe and effective in children.

IMPORTANT SAFETY INFORMATION

CAMZYOS (mavacamten) may cause serious side effects, including:

Heart failure, a condition where the heart cannot pump with enough force. Heart failure is a serious condition that can lead to death. You must have echocardiograms before you take your first dose and during your treatment with CAMZYOS to help your healthcare provider understand how your heart is responding to CAMZYOS. People who develop a serious infection or irregular heartbeat have a greater risk of heart failure during treatment with CAMZYOS. Tell your healthcare provider or get medical help right away if you develop new or worsening shortness of breath, chest pain, fatigue, swelling in your legs, a racing sensation in your heart (palpitations), or rapid weight gain.

The risk of heart failure is also increased when CAMZYOS is taken with certain other medications. Tell your healthcare provider about the medicines you take, both prescribed and obtained over-the-counter, before and during treatment with CAMZYOS.

Because of the serious risk of heart failure, CAMZYOS is only available through a restricted program called the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program.

•    Your healthcare provider must be enrolled in the CAMZYOS REMS Program in order for you to be prescribed

CAMZYOS.

•    Before you take CAMZYOS, you must enroll in the CAMZYOS REMS Program. Talk to your healthcare provider about how to enroll in the CAMZYOS REMS Program. You will be given information about the program when you enroll.

•    Before you take CAMZYOS, your healthcare provider and pharmacist will make sure you understand how to

take CAMZYOS safely, which will include returning for echocardiograms when advised by your healthcare provider.

•    CAMZYOS can only be dispensed by a certified pharmacy that participates in the CAMZYOS REMS

Program. Your healthcare provider can give you information on how to find a certified pharmacy. You will not be able to get CAMZYOS at a local pharmacy.

•    If you have questions about the CAMZYOS REMS Program, ask your healthcare provider, visit

www.CAMZYOSREMS.com, or call 1-833-628-7367.

#risingawareness #heartdisease #drwilliamcrowder #stephanie #heartfailure #medicine #hcm #symptoms #camzyos

The post RAISING AWARENESS OF AN OFTEN UNDERDIAGNOSED HEART DISEASE DURING HEART MONTH IN FEBRUARY appeared first on Good News!.

What are diabetes home tests?

Testing blood glucose, also known as blood sugar, is an essential part of your diabetes care plan.

Depending on your current condition, you may need to visit your doctor several times a year for formal testing, according to the American Diabetes Association. You may also need to reach out to your doctor for preventive testing, such as cholesterol checks and eye exams.

While staying in touch with your doctor is important for staying on top of your treatment plan, you can and should test your blood sugar on your own as long as your healthcare team advises you to.

Self-monitoring your blood glucose may be vital to your treatment. Testing your own levels allows you to learn how to manage your blood sugar regardless of the time of day or where you are.

Learn how these tests work and talk with your doctor about the benefits of self-monitoring.

The post The latest diabetes stories for you appeared first on Good News!.

HOWEVER, DESPITE THE POTENTIAL BENEFITS, SOME PATIENTS STILL FEEL EMBARRASSED BY THEIR SKIN. MANY WILL CHOOSE TO COVER UP WITH MORE CLOTHING OR AVOID SOCIAL SITUATIONS ALTOGETHER.

BUT EVERYONE DESERVES TO HAVE FUN IN THE SUN. JOINING US NOW IS HEALTH CARE PROVIDER, MELINDA GREENFIELD, WITH HOW MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS CAN MAKE THE MOST OF WARM WEATHER.

BIO-Dr. Melinda Greenfield Bio

Dr. Melinda Greenfield is a Board Certified Dermatologist in private practice since 1999. She has offices in Ponte Vedra Beach, FL and Albany, GA and has an online Telehealth practice in nine states.

Dr. Greenfield attended The University of Maryland for her undergraduate degree and Nova Southeastern University for Medical School. She completed her internship at Sinai Hospital of Baltimore and her Dermatology residency at St. Barnabas Hospital in the Bronx, NY.

Dr. Greenfield is past president of the Dougherty County Medical Society, the Georgia Osteopathic Medical society and previously served on the Editorial Board of the Journal of the American Osteopathic College of Dermatology.

Dr. Greenfield is a clinical assistant professor at The Georgia Campus of the Philadelphia College of Osteopathic Medicine, The Medical College of Georgia, PCOM South Georgia and The Orlando College of Osteopathic Medicine. She teaches the second-year dermatology curriculum to medical students and has students and residents rotate in her office throughout the year.

Dr. Greenfield has lectured at multiple meetings throughout the years and has authored four publications. She participated in an episode of The Balancing Act on Lifetime TV that highlighted psoriasis and is on the Speaker Board for several pharmaceutical companies.

In her free time, Dr. Greenfield enjoys bike riding, working out in the gym, gardening, cooking and spending time with her family.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA^® (tildrakizumab-asmn)?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

• feel faint
• trouble breathing or throat tightness
• swelling of your face, eyelids, lips, mouth, tongue or throat
• chest tightness
• skin rash

What is ILUMYA?

ILUMYA is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION (continued)

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

• fever, sweats, or chills
• muscle aches
• weight loss
• cough
• warm, red, or painful skin or sores on your body different from your psoriasis
• diarrhea or stomach pain
• shortness of breath
• burning when you urinate or urinating more often than normal
• blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
• have an infection that does not go away or that keeps coming back
• have TB or have been in close contact with someone with TB
• recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
• are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include: upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the full Prescribing Information and Medication Guide for ILUMYA and discuss any questions with your doctor.

#warmerweather #psoriasis #tips #skin #plaque #symptoms #sunlight #embarrassed #drmelindagreenfield #patients #healthcare #medical #sinaihospital #ilumya #tildrakizumab-asmn

The post IT’S MORE THAN SKIN DEEP How Warmer Weather Affects Psoriasis & Tips to Help Those Impacted appeared first on Good News!.

For the millions of people living with psoriasis, like Gloria, the impact on their daily lives extends far beyond the physical symptoms. Among some of the many grievances Gloria can share about her last 10 years living with the condition are:

Strangers commenting on her skin when she’s out in public

Leaving bits of skin on furniture — and even needing to vacuum her bedsheets

Wearing her hair down during the unbearably hot Texas summer to avoid showing affected areas on the back of her neck

Times when people haven’t wanted to touch her skin, such as a cashier not wanting to take a $20 bill from her hands, during a flare-up

Although Gloria tried a number of treatments to help improve her psoriasis, many of these treatments didn’t give her the results she was looking for — as is often the case among psoriasis patients.

Fortunately, there’s hope. A new, innovative treatment in plaque psoriasis is getting high praise from people like Gloria, as well as the medical community. Following more than 25 years of minimal innovation in the topical psoriasis treatment space, the FDA recently approved a steroid-free, prescription cream for plaque psoriasis in adults — the first in its class in the U.S.

Linda Stein-Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System and Gloria as they discuss the significant impact plaque psoriasis may have on a person’s life and what this new treatment may mean for those who are suffering with plaque psoriasis as well.

Interview is courtesy: Dermavant Sciences

#plaquepsoriasis #psoriasis #advocate #chronicinflammatorydisease #patchesofskin #itchy #painful #disfiguring #gloria #physicalsymptoms #drlindastein-gold #health #clinical #dermavantsciences

The post The Truth About Living with Plaque Psoriasis And How to Become Your Own Advocate appeared first on Good News!.